NCT06727058 - Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | Biotech Hunter

Enrollment

276

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

December 11, 2025

Study Completion Date

October 13, 2026

Conditions

Influenza Immunization

Interventions

BIOLOGICAL

Pandemic flu H5 mRNA vaccine

"Pharmaceutical Form: Suspension for injection~Route of Administration: Intramuscular (IM)"

OTHER

Placebo

"Pharmaceutical Form: Liquid solution for injection~Route of Administration: Intramuscular (IM)"

Trial Locations (14)

22911

Charlottesville Medical Research- Site Number : 8400005, Charlottesville

29405

Coastal Carolina Research Center - North Charleston- Site Number : 8400001, North Charleston

30342

Atlanta Clinical Research Center- Site Number : 8400007, Atlanta

32720

Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400002, DeLand

33777

Accel Research Sites - St. Petersburg- Site Number : 8400004, Largo

33803

ARSN-Lakeland CRU- Site Number : 8400006, Lakeland

45246

Velocity Clinical Research - Springdale- Site Number : 8400010, Cincinnati

48334

QUEST Research Institute- Site Number : 8400014, Bingham Farms

68134

Velocity Clinical Research - Omaha- Site Number : 8400012, Omaha

68701

Velocity Clinical Research - Norfolk- Site Number : 8400015, Norfolk

77479

Olympus Clinical Research - Sugar Land- Site Number : 8400009, Sugar Land

84088

Velocity Clinical Research, Salt Lake City- Site Number : 8400011, West Jordan

91942

Velocity Clinical Research - San Diego- Site Number : 8400013, La Mesa

30030-2627

Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400003, Decatur

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY